INMB - INmune Bio Inc. (INMB) Q1 2024 Earnings Call Transcript
2024-05-11 20:58:06 ET
INmune Bio, Inc. (INMB)
Q1 2024 Results Conference Call
May 9, 2024 04:30 PM ET
Company Participants
David Moss - Chief Financial Officer
Dr. RJ Tesi - Chief Executive Officer and Co-Founder
Dr. Mark Lowdell - Chief Scientific Officer
Conference Call Participants
Tom Shrader - BTIG
Joel Beatty - Baird
Jason McCarthy - Maxim Group
Daniel Carlson - Tailwinds Research
Presentation
Operator
Greetings and welcome to the INmune Bio First Quarter 2024 Earnings Call. At the end of the presentation, there will be a question-and-answer session. [Operator Instructions] As a reminder this conference is being recorded. A transcript will follow within 24 hours of this conference call.
At this time, it is my pleasure to introduce Mr. David Moss, CFO of INmune Bio. David?
David Moss
Thank you, James, and good afternoon, everybody. We thank you for joining us for the call for INmune Bio's first quarter 2024 financial results. With me on the call is Dr. RJ Tesi, CEO and Co-Founder of INmune Bio and Dr. Mark Lowdell, Chief Scientific Officer and Co-Founder of INmune Bio, who will provide an update on INKmune, our memory-like natural killer cell oncology platform.
Before we begin, I remind everyone that except for statements of historical fact, the statements made by management and responses to questions on this conference call are forward-looking statements under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that can cause actual results to differ materially from those such as forward-looking statements.
Please see the forward-looking statements disclaimer on the Company's earnings press release, as well as risk factors in the Company's SEC filings including our most recent quarterly filings with the SEC. There is no assurance of any specific outcome. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made as the facts and circumstances underlying these forward-looking statements may change. Except as required by law, INmune Bio disclaims any obligations to update these forward-looking statements to reflect future information events or circumstances.
With that behind us, now I'd like to turn the call over to Dr. RJ Tesi, CEO of INmune Bio. RJ?...
INmune Bio, Inc. (INMB) Q1 2024 Earnings Call Transcript